Patient-Reported Quality of Life, Depression, Anxiety, and Physical Activity in Patients Receiving an Implantable Cardioverter-Defibrillator for Primary versus Secondary Prevention: A Single-Centre, Prospective, Observational Cohort Study
Abstract
:1. Introduction
2. Materials and Methods
- Inactive—participants are insufficiently active (have an activity level below the minimally active level);
- Minimally active—(a) 3 or more days of vigorous physical activity for 20 min per day; or (b) 5 or more days of moderate-intensity physical activity and/or a short walk for at least 30 min per day; (c) or 5 or more days of any combination, reaching at least 600 MET-min/week;
3. Results
4. Discussion
5. Conclusions
- The type of prevention: primary vs. secondary, as an indication for an implantable cardioverter-defibrillator or cardiac resynchronization therapy defibrillator does not affect levels of anxiety, stress, nor depression;
- Patients with implantation for secondary prevention are significantly less physically active after implantation than those for primary prevention. Lower physical activity is associated additionally with the higher NYHA class and the incidence of chronic kidney disease;
- Quality of life of patients after implantation for secondary prevention is lower than in subjects with primary prevention.
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.F.; Coats, A.J.S.; Falk, V.; González-Juanatey, J.R.; Harjola, V.-P.; Jankowska, E.A.; et al. 2016 ESC Guidelines for the diagnosis and treatment of acute chronic heart failure. Eur. Heart J. 2016, 37, 2129–2200. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Maciąg, A.; Przybylski, A.; Sterliński, M.; Lewandowski, M.; Gepner, K.; Kowalik, I.; Derejko, P.; Pytkowski, M.; Szumowski, L.; Szwed, H. QRS complex widening as a predictor of appropriate implantable cardioverter−defibrillator (ICD) therapy and higher mortality risk in primary prevention ICD patients. Kardiol. Pol. 2012, 70, 360–368. [Google Scholar] [PubMed]
- Pedersen, S.S.; van Domburg, R.T.; Theuns, D.A.; Jordaens, L.; Erdman, R.A. Concerns about the implantable cardioverter defibrillator: A determinant of anxiety and depressive symptoms independent of experienced shocks. Am. Heart J. 2005, 149, 664–669. [Google Scholar] [CrossRef] [PubMed]
- Sears, S.F.; Matchett, M.; Conti, J.B. Effective management of ICD patient psychosocial issues and patient critical events. J. Cardiovasc. Electrophysiol. 2009, 20, 1297–1304. [Google Scholar] [CrossRef] [PubMed]
- Lomper, K.; Sławuta, A.; Dudek, K.; Mazur, G.; Walfridsson, U.; Jankowska-Polańska, B. Psychometric evaluation of the Polish version of the Arrhythmia-Specific Questionnaire in Tachycardia and Arrhythmia: A new tool for symptom and health-related quality of life assessment. Kardiol. Pol. 2019, 77, 541–552. [Google Scholar] [CrossRef] [PubMed]
- Kamphuis, H.C.M.; De Leeuw, J.R.J.; Derksen, R.; Hauer, R.N.W.; Winnubst, J.A.M. Implantable cardioverter defibrillator recipients: Quality of life in recipients with and without ICD shock delivery: A prospective study. Europace 2003, 5, 381–389. [Google Scholar] [CrossRef]
- Smolis-Bąk, E.; Dąbrowski, R.; Piotrowicz, E.; Chwyczko, T.; Dobraszkiewicz-Wasilewska, B.; Kowalik, I.; Kazimierska, B.; Jędrzejczyk, B.; Smolis, R.; Gepner, K.; et al. Hospital-based and telemonitoring guided home-based training programs: Effects on exercise tolerance and quality of life in patients with heart failure (NYHA class III) and cardiac resynchronization therapy. A prospective observation. Int. J. Cardiol. 2015, 199, 442–447. [Google Scholar] [CrossRef] [PubMed]
- Smolis-Bąk, E.; Chwyczko, T.; Kowalik, I.; Borowiec, A.; Maciąg, A.; Szwed, H.; Dąbrowski, R. Exercise training program in patients with NYHA III class systolic heart failure—Parallel comparison to the effects of resynchronization therapy. Adv. Med. Sci. 2019, 64, 241–245. [Google Scholar] [CrossRef] [PubMed]
- Davids, J.S.; McPherson, C.A.; Earley, C.; Batsford, W.P.; Lampert, R. Benefits of cardiac rehabilitation in patients with implantable cardioverter-defibrillators: A patient survey. Arch. Phys. Med. Rehabil 2005, 86, 1924–1928. [Google Scholar] [CrossRef] [PubMed]
- Isaksen, K.; Morken, I.M.; Munk, P.S.; Larsen, A.I. Exercise training and cardiac rehabilitation in patients with implantable cardioverter defibrillators: A review of current literature focusing on safety, effects of exercise training, and the psychological impact of programme participation. Eur. J. Prev. Cardiol. 2012, 19, 804–812. [Google Scholar] [CrossRef] [PubMed]
- Hagströmer, M.; Oja, P.; Sjöström, M. The International Physical Activity Questionnaire (IPAQ): A studyof concurrent and construct validity. Public Health Nutr. 2006, 9, 755–762. [Google Scholar] [CrossRef] [PubMed]
- Lee, P.H.; Macfarlane, D.J.; Lam, T.H.; Stewart, S.M. Validity of the international physical activity questionnaire short form (IPAQ-SF): A systematic review. Int. J. Behav. Nutr. Phys. Act. 2011, 8, 115. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gierlaszyńska, K.; Pudlo, R.; Jaworska, I.; Byrczek-Godula, K.; Gąsior, M. Tools for assessing quality of life in cardiology and cardiac surgery. Kardiochir. Torakochir. Pol. 2016, 13, 78–82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kania, J.; Wąsek, W.; Piotrowicz, K.; Krzesiński, P. Impact of anxiety-trait level and coping styles on a Six-Minute Walk Test in patients undergoing cardiac rehabilitation. Kardiol. Pol. 2022; Epub ahead of print. [Google Scholar] [CrossRef]
- Sobański, P.Z.; Rajszys, G.B.; Grodzicki, T.; Jakubów, P.; Jankowski, P.; Kurzyna, M.; Nessler, J.; Przybylski, A.; Ratajska, A.; Pająk, L.T.; et al. Palliative care for people living with cardiac disease. Kardiol. Pol. 2020, 78, 364–373. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rahmawati, A.; Chishaki, A.; Ohkusa, T.; Rn, H.S.; Rn, M.T.; Ohtsuka, Y.; Nakai, M.; Miyazono, M.; Rn, N.H.; Sakurada, H.; et al. Influence of primary and secondary prevention indications on anxiety about the implantable cardioverter-defibrillator. J. Arrhythm. 2016, 32, 102–107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berg, S.K.; Thygesen, L.C.; Svendsen, J.H. Anxiety predicts mortality in ICD patients: Results from the cross-sectional national CopenHeartICD survey with register follow-up. PACE 2014, 37, 1641–1650. [Google Scholar] [CrossRef] [PubMed]
- Freedenberg, V.; Thomas, S.A.; Friedmann, E. Anxiety and depression in implanted cardioverter-defibrillator recipients and heart failure: A review. Heart Fail. Clin. 2011, 7, 59–68. [Google Scholar] [CrossRef] [PubMed]
- Pedersen, S.S.; Sears, S.F.; Burg, M.M.; Van Den Broek, K.C. Does ICD indication affect quality of life and levels of distress? PACE 2009, 32, 153–156. [Google Scholar] [CrossRef] [PubMed]
- Da Silva, K.R.; Costa, R.; Rodrigues, C.G.; Schasechter, A.; Nobre, M.; Passman, R.; Mark, D.B. Quality of life in patients with implantable cardioverter-defibrillator: Systematic review of randomized controlled trials. Eur. J. Cardiovasc. Nurs. 2018, 17, 196–206. [Google Scholar] [CrossRef] [PubMed]
Primary Prevention n = 74 (66.7%) | Secondary Prevention n = 37 (33.3%) | p Value | |
---|---|---|---|
Age | 59.6 ± 14.0 | 65.3 ± 13.2 | 0.043 |
Male | 63 (85.1%) | 31 (83.8%) | 0.852 |
Weight (kg) | 88.7 ± 18.9 | 85.8 ± 14.3 | 0.409 |
Height (cm) | 173.6 ± 8.3 | 172.8 ± 6.8 | 0.624 |
BMI (kg/m2) | 29.3 ± 5.3 | 28.6 ± 3.8 | 0.482 |
Coronary artery disease | 45 (61.6%) | 24 (64.9%) | 0.741 |
Myocardial infarction | 43 (58.1%) | 22 (59.5%) | 0.892 |
Revascularization | 28 (37.8%) | 20 (54.1%) | 0.104 |
Kidney disease | 11 (14.9%) | 3 (8.1%) | 0.379 |
Dyslipidemia | 12 (16.2%) | 4 (10.8%) | 0.445 |
Thyroid disease | 9 (12.2%) | 8 (21.6%) | 0.192 |
DM | 23 (31.1%) | 3 (8.1%) | 0.007 |
Hypertension | 24 (32.4%) | 13 (35,1%) | 0.776 |
Ventricular arrhythmias | 26 (35.1%) | 24 (64.9%) | 0.003 |
AF | 26 (35.1%) | 4 (10.8%) | 0.006 |
Valve disorder | 13 (17.8%) | 3 (8.1%) | 0.173 |
LVEF (%) | 31 ± 13 | 34 ± 10 | 0.197 |
ICD | 46 (62.2%) | 33 (89.2%) | 0.002 |
CRT-D | 28 (37.8%) | 4 (10.8%) | |
Appropriate interventions * ICD/CRT-D | 25 (33.8%) | 18 (48.6%) | 0.130 |
Inappropriate † interventions ICD/CRT-D | 10 (13.5%) | 4 (10.8%) | 0.771 |
Time after implantation (years) | 6.5 [5.0–9.0] | 5.0 [3.0–10.0] | 0.476 |
NYHA | P-Cochran Armitage Trend Test | ||||
---|---|---|---|---|---|
NYHA Primary prevention | I 3 (50%) | II 40 (59.7%) | III 26 (81.2%) | IV 5 (83.3%) | 0.020 |
Secondary prevention | 3 (50%) | 27 (40.3%) | 6 (18.7%) | 1 (16.7%) |
Primary Prevention—before Implantation n = 74 (66.7%) | Secondary Prevention—before Implantation n = 37 (33.3%) | p Value | Primary Prevention—after Implantation n = 74 (66.7%) | Secondary Prevention—after Implantation n = 37 (33.3%) | p Value | |
---|---|---|---|---|---|---|
Spending time actively | 58 (79.5%) | 31 (83.8%) | 0.585 | 58 (79.4%) | 17 (47.2%) | 0.0006 |
Walking | 33 (44.6%) | 16 (43.2%) | 0.893 | 44 (59.5%) | 13 (35.1%) | 0.016 |
Cycling | 29 (39.2%) | 14 (37.8%) | 0.890 | 19 (25.7%) | 2 (5.4%) | 0.010 |
Swimming | 8 (10.8%) | 3 (8.1%) | 0.749 | 3 (4.1%) | 0 (0%) | 0.549 |
Dancing | 5 (6.8%) | 1 (2.7%) | 0.662 | 2 (2.7%) | 0 (0%) | 0.551 |
Gymnastics | 3 (4.1%) | 2 (8.4%) | 1.00 | 2 (2.7%) | 1 (2.7%) | 1.00 |
Running | 2 (2.7%) | 1 (2.7%) | 1.00 | 0 (0%) | 0 (0%) | NA |
Frequency | ||||||
1–2 times per week | 16 (27.6%) | 8 (25.8%) | 0.813 | 15 (25.9%) | 6 (35.3%) | 0.678 |
3–4 times per week | 15 (25.9%) | 10 (32.3%) | 12 (20.7%) | 4 (23.5%) | ||
Every day | 27 (46.5%) | 13 (41.9%) | 31 (53.4%) | 7 (41.2%) | ||
Duration | ||||||
30 min | 11 (19.0%) | 6 (19.3%) | 0.729 | 14 (24.1%) | 3 (17.6%) | 0.708 |
0.5–1 h | 18 (31.0%) | 12 (38.7%) | 18 (31.0%) | 7 (41.2%) | ||
>1 h | 29 (50.0%) | 13 (41.9%) | 26 (44.8%) | 7 (41.2%) |
Primary Prevention n = 74 (66.7%) | Secondary Prevention n = 37 (33.3%) | p Value | |
---|---|---|---|
Vigorous | 0 (0–480) | 0 (0–0) | 0.196 |
Moderate | 390 (0–1200) | 360 (0–2160) | 0.545 |
Light (walk) | 2772 (1188–4158) | 2772 (693–4158) | 0.528 |
Total | 4065 (1584–8638) | 3252 (2160–6426) | 0.717 |
Activity category | |||
Inactive; insufficiently active | 13 (17.6%) | 4 (11.4%) | 0.650 |
Minimally active; sufficiently active | 19 (25.7%) | 11 (31.4%) | |
HEPA active; highly active | 42 (56.8%) | 20 (57.1%) |
Activity Category | p | |||
---|---|---|---|---|
Inactive, Insufficiently Active | Minimally Active, Sufficiently Active | HEPA Active, Highly Active | ||
NYHA III or IV amb. | 11 (57.9%) | 9 (30.0%) | 18 (29.2%) | 0.042 |
Thyroid diseases | 5 (26.3%) | 5 (16.7%) | 7 (11.3%) | 0.112 |
Diabetes | 6 (31.6%) | 8 (26.7%) | 12 (19.3%) | 0.231 |
Chronic kidney disease | 5 (26.3%) | 9 (9.8%) | 0.049 |
Primary Prevention n = 74 (66.7%) | Secondary Prevention n = 37 (33.3%) | p Value | |
---|---|---|---|
Energy | 24.0 (0–63.2) | 60.8 (0.0–76.0) | 0.358 |
Pain | 0.0 (0.0–17.0) | 9.0 (0.0–30.0) | 0.082 |
Emotional reactions | 9.8 (0.0–30.4) | 16.5 (0.0–31.5) | 0.544 |
Sleep disturbances | 34.3 (0–77.6) | 22.4 (0.0–65.1) | 0.625 |
Social isolation | 0 (0–22.0) | 0 (0–22.0) | 0.512 |
Physical mobility | 21.4 (0–42.8) | 21.8 (10.8–45.2) | 0.352 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Krauze, N.; Smolis-Bąk, E.; Kowalik, I.; Sterliński, M. Patient-Reported Quality of Life, Depression, Anxiety, and Physical Activity in Patients Receiving an Implantable Cardioverter-Defibrillator for Primary versus Secondary Prevention: A Single-Centre, Prospective, Observational Cohort Study. Int. J. Environ. Res. Public Health 2022, 19, 12830. https://doi.org/10.3390/ijerph191912830
Krauze N, Smolis-Bąk E, Kowalik I, Sterliński M. Patient-Reported Quality of Life, Depression, Anxiety, and Physical Activity in Patients Receiving an Implantable Cardioverter-Defibrillator for Primary versus Secondary Prevention: A Single-Centre, Prospective, Observational Cohort Study. International Journal of Environmental Research and Public Health. 2022; 19(19):12830. https://doi.org/10.3390/ijerph191912830
Chicago/Turabian StyleKrauze, Natasza, Edyta Smolis-Bąk, Ilona Kowalik, and Maciej Sterliński. 2022. "Patient-Reported Quality of Life, Depression, Anxiety, and Physical Activity in Patients Receiving an Implantable Cardioverter-Defibrillator for Primary versus Secondary Prevention: A Single-Centre, Prospective, Observational Cohort Study" International Journal of Environmental Research and Public Health 19, no. 19: 12830. https://doi.org/10.3390/ijerph191912830